| Name | Title | Contact Details |
|---|---|---|
Peter Wang |
Chief Technology Officer | Profile |
Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Mavericks highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
Helicos BioSciences Corporation is developing instruments for ultra-high-throughput sequencing of DNA or RNA without amplification.
CORTEX Scientific Botanicals is a Ojai, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Squip is a Lebanon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.